Clinical trial
A Controlled Pregabalin Trial In Fibromyalgia
NCT00230776 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00230776 |
|---|---|
| Title | A Controlled Pregabalin Trial In Fibromyalgia |
| Official title | A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibromyalgia |
| Intervention type | Drug |
| Interventions | pregabalin, placebo |
| Enrollment | 740 |
| Start date | Oct 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Oct 3, 2005 |
| Last update posted | Jan 26, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: